184 related articles for article (PubMed ID: 10903391)
1. Dopamine agonists in the treatment of Parkinson s disease past, present and future.
Sit SY
Curr Pharm Des; 2000 Aug; 6(12):1211-48. PubMed ID: 10903391
[TBL] [Abstract][Full Text] [Related]
2. Clinical pharmacology of dopamine agonists in Parkinson's disease.
Lange KW
Drugs Aging; 1998 Nov; 13(5):381-9. PubMed ID: 9829165
[TBL] [Abstract][Full Text] [Related]
3. Dopamine agonists and Parkinson's disease.
Burton K; Calne DB
Clin Neurol Neurosurg; 1984; 86(3):172-7. PubMed ID: 6091965
[TBL] [Abstract][Full Text] [Related]
4. Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group.
Parkinson Study Group
JAMA; 2000 Oct; 284(15):1931-8. PubMed ID: 11035889
[TBL] [Abstract][Full Text] [Related]
5. Dopamine agonists.
Tuite P; Ebbitt B
Semin Neurol; 2001; 21(1):9-14. PubMed ID: 11346030
[TBL] [Abstract][Full Text] [Related]
6. The role of dopamine agonists in early Parkinson's disease.
Watts RL
Neurology; 1997 Jul; 49(1 Suppl 1):S34-48. PubMed ID: 9222273
[TBL] [Abstract][Full Text] [Related]
7. Plausible improvements for selective targeting of dopamine receptors in therapy of Parkinson's disease.
Luthra PM; Kumar JB
Mini Rev Med Chem; 2012 Dec; 12(14):1556-64. PubMed ID: 22697513
[TBL] [Abstract][Full Text] [Related]
8. Current status of dopamine agonists in Parkinson's disease management.
Montastruc JL; Rascol O; Senard JM
Drugs; 1993 Sep; 46(3):384-393. PubMed ID: 7693430
[TBL] [Abstract][Full Text] [Related]
9. [Dopaminergic agonists in the treatment of Parkinson's disease].
Supiot F; Sternon J; Zegers de Beyl D
Rev Med Brux; 2000 Dec; 21(6):493-9. PubMed ID: 11194495
[TBL] [Abstract][Full Text] [Related]
10. Long-term studies of dopamine agonists.
Hubble JP
Neurology; 2002 Feb; 58(4 Suppl 1):S42-50. PubMed ID: 11909984
[TBL] [Abstract][Full Text] [Related]
11. Use of apomorphine in Parkinson's disease.
Stocchi F
Neurol Sci; 2008 Dec; 29 Suppl 5():S383-6. PubMed ID: 19381769
[TBL] [Abstract][Full Text] [Related]
12. An evidence-based review of dopamine receptor agonists in the treatment of Parkinson's disease.
Deleu D; Northway MG; Hanssens Y
Saudi Med J; 2002 Oct; 23(10):1165-75. PubMed ID: 12436117
[TBL] [Abstract][Full Text] [Related]
13. Combination of two different dopamine agonists in the management of Parkinson's disease.
Stocchi F; Berardelli A; Vacca L; Thomas A; De Pandis MF; Modugno N; Valente M; Ruggieri S
Neurol Sci; 2002 Sep; 23 Suppl 2():S115-6. PubMed ID: 12548370
[TBL] [Abstract][Full Text] [Related]
14. Are dopamine receptor agonists neuroprotective in Parkinson's disease?
Le WD; Jankovic J
Drugs Aging; 2001; 18(6):389-96. PubMed ID: 11419913
[TBL] [Abstract][Full Text] [Related]
15. Alternatives to levodopa in the initial treatment of early Parkinson's disease.
Lees A
Drugs Aging; 2005; 22(9):731-40. PubMed ID: 16156677
[TBL] [Abstract][Full Text] [Related]
16. Pharmacologic profile of ropinirole: a nonergoline dopamine agonist.
Tulloch IF
Neurology; 1997 Jul; 49(1 Suppl 1):S58-62. PubMed ID: 9222275
[TBL] [Abstract][Full Text] [Related]
17. [Are dopamine agonists alternative therapy for levodopa in early stage of Parkinson's disease? No].
Friedman A
Neurol Neurochir Pol; 2007; 41(2 Suppl 1):S10-3. PubMed ID: 17941453
[TBL] [Abstract][Full Text] [Related]
18. New directions in the drug treatment of Parkinson's disease.
Montastruc JL; Rascol O; Senard JM
Drugs Aging; 1996 Sep; 9(3):169-84. PubMed ID: 8877311
[TBL] [Abstract][Full Text] [Related]
19. [The role of dopaminagonists in the treatment of Parkinson's disease].
Ransmayr G
Praxis (Bern 1994); 2005 Oct; 94(42):1633-8. PubMed ID: 16277084
[TBL] [Abstract][Full Text] [Related]
20. Second generation of dopamine agonists: pros and cons.
Rabey JM
J Neural Transm Suppl; 1995; 45():213-24. PubMed ID: 8748628
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
